


HDAC-IN-48

Cat. No.:	HY-151872
Molecular Formula:	C ₁₃ H ₁₇ N ₃ O ₃ S
Molecular Weight:	295.36
Target:	HDAC; Ferroptosis
Pathway:	Cell Cycle/DNA Damage; Epigenetics; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	<p>HDAC-IN-48 is a potent HDAC inhibitor. HDAC-IN-48 is a hybrid molecule with great cytotoxic profile (GI₅₀~20 nM). HDAC-IN-48 consists of pharmacophores of SAHA and CETZOLE molecules. HDAC-IN-48 induces ferroptosis and inhibits HDAC proteins^[1]. HDAC-IN-48 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAC) with molecules containing Azide groups.</p>																
In Vitro	<p>HDAC-IN-48 (0-40 μM; 3 d) has superior antiproliferative activity on cancer cells (NCI-H522 and HCT-116) vs the normal cells (WI38 and RPE) with IC₅₀s of 0.5 μM (NCI-H522), 0.61 μM (HCT-116), 8.37 μM (WI38, normal human lung fibroblasts), and 6.13 μM (RPE, retinal pigment epithelial cells), respectively^[1].</p> <p>HDAC-IN-48 (2.5 μM; 24 h) suppresses cell viability by inducing ferroptosis and HDAC inhibition^[1].</p> <p>HDAC-IN-48 (10 μM; 6 h) decreases the lipid peroxide level compared with SAHA^[1].</p> <p>HDAC-IN (0.58 μM, 1.16 μM, and 2.32 μM; 3 d) has no neurotoxic effects and (2.5, 5, and 10 μM; 3 d) leads to hyperacetylation of histones and tubulin^[1].</p> <p>Nondifferentiated PC-12 cells have stem-like properties, but when differentiated by a nerve growth factor, they demonstrate neuronal behavior. HDAC-IN-48 (0.58 μM, 1.16 μM, and 2.32 μM; 24 h) behaves as the HDAC control effect, shows few ferroptosis induction on both differentiated and undifferentiated PC-12 cells^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Western Blot Analysis^[1]</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Cell Line:</td> <td>NCI-H522 cells</td> </tr> <tr> <td>Concentration:</td> <td>2.5, 5, and 10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>72 hours; at the corresponding concentrations in the presence of Lipoxstatin-1 (0.25 μM)</td> </tr> <tr> <td>Result:</td> <td>Led to hyperacetylation of histones and tubulin in a similar way to SAHA (pan-inhibitor).</td> </tr> </table> <p>Cell Viability Assay^[1]</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Cell Line:</td> <td>NCI-H522, WI38, HCT-116, and RPE</td> </tr> <tr> <td>Concentration:</td> <td>0-40 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>72 hours</td> </tr> <tr> <td>Result:</td> <td>Showed selectivity among normal cells over cancer cells.</td> </tr> </table>	Cell Line:	NCI-H522 cells	Concentration:	2.5, 5, and 10 μM	Incubation Time:	72 hours; at the corresponding concentrations in the presence of Lipoxstatin-1 (0.25 μM)	Result:	Led to hyperacetylation of histones and tubulin in a similar way to SAHA (pan-inhibitor).	Cell Line:	NCI-H522, WI38, HCT-116, and RPE	Concentration:	0-40 μM	Incubation Time:	72 hours	Result:	Showed selectivity among normal cells over cancer cells.
Cell Line:	NCI-H522 cells																
Concentration:	2.5, 5, and 10 μM																
Incubation Time:	72 hours; at the corresponding concentrations in the presence of Lipoxstatin-1 (0.25 μM)																
Result:	Led to hyperacetylation of histones and tubulin in a similar way to SAHA (pan-inhibitor).																
Cell Line:	NCI-H522, WI38, HCT-116, and RPE																
Concentration:	0-40 μM																
Incubation Time:	72 hours																
Result:	Showed selectivity among normal cells over cancer cells.																

Inhibited cell survival with IC50s of 0.5 μ M, 8.37 μ M, 0.61 μ M, and 6.13 μ M.

Apoptosis Analysis^[1]

Cell Line: NCI-H522 cells

Concentration: 5 μ M

Incubation Time: 24 hours, 48 hours, and 72 hours

Result: Induced cell ferroptosis.

REFERENCES

[1]. Karaj E, et al. First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids. J Med Chem. 2022 Nov 10;65(21):14764-14791.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA